Early Detection and Evidence-Based Pharmacotherapy for Postpartum Depression in Primary Care
Annenberg Center for Health Sciences
6 episodes
5 days ago
This activity, developed by family medicine and mental health clinicians, discusses team-based screening recommendations, along with strategies for overcoming barriers in diagnosis, are applied to primary care practice. The risks and benefits of treatment, including nonpharmacologic and pharmacologic options, such as selective serotonin reuptake inhibitors and neuroactive steroid gamma-aminobutyric acid A receptor positive modulators, are discussed, to enable the development of a personalized care plan using a collaborative care model.
All content for Early Detection and Evidence-Based Pharmacotherapy for Postpartum Depression in Primary Care is the property of Annenberg Center for Health Sciences and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This activity, developed by family medicine and mental health clinicians, discusses team-based screening recommendations, along with strategies for overcoming barriers in diagnosis, are applied to primary care practice. The risks and benefits of treatment, including nonpharmacologic and pharmacologic options, such as selective serotonin reuptake inhibitors and neuroactive steroid gamma-aminobutyric acid A receptor positive modulators, are discussed, to enable the development of a personalized care plan using a collaborative care model.
Early Detection and Evidence-Based Pharmacotherapy for Postpartum Depression in Primary Care
7 minutes 3 seconds
1 year ago
Personalizing Pharmacotherapy
General guidelines
Early Detection and Evidence-Based Pharmacotherapy for Postpartum Depression in Primary Care
This activity, developed by family medicine and mental health clinicians, discusses team-based screening recommendations, along with strategies for overcoming barriers in diagnosis, are applied to primary care practice. The risks and benefits of treatment, including nonpharmacologic and pharmacologic options, such as selective serotonin reuptake inhibitors and neuroactive steroid gamma-aminobutyric acid A receptor positive modulators, are discussed, to enable the development of a personalized care plan using a collaborative care model.
